



# OECI Accreditation & Designation and Minimum Volumes

**Prof. Wim H. van Harten**  
**Athens June 2025**



## Volume matters, sufficient evidence


- ❖ Mechanisms presumed, but not known in detail
- ❖ Statistical variation confuses the discussion
- ❖ Strong alliances needed to enforce concentration decisions (Denmark, Ireland, Princess Maxima, Literature)
- ❖ Case Netherlands norms established for 5 tumor types
- ❖ Too early for quantitative A&D norms.



# The Effect of Provider Case Volume on Cancer Mortality: Systematic Review and Meta-Analysis. *Cancer 2009*

[Russell L. Gruen MBBS, PhD](#), [Veronica Pitt PhD](#), [Sally Green PhD](#), [Anne Parkhill MBIT, GradDipLib](#), [Donald Campbell MMedSci \(ClinEpi\), MD](#), [Damien Jolley MSc \(Epidemiol\), MSc \(Stats\), DipEd, AStat](#)

- 101 publications involving greater than 1 million patients with esophageal, gastric, hepatic, pancreatic, colon, or rectal cancer, of whom more than 70,000 died
- A significant volume effect was evident for the majority of gastrointestinal cancers; with each doubling of hospital case volume, the odds of perioperative death decreased by 0.1 to 0.23
- Between 10 and 50 patients per year, depending on cancer type, needed to be moved from a “low-volume” hospital to a “high-volume” hospital to prevent 1 additional volume-associated perioperative death.
- One-third of all analyses did not find a significant volume effect on mortality
- More direct quality measures and the validity of their use to inform policy should also be explored



# Cancer

An International Interdisciplinary  
Journal of the American Cancer Society

## Effect of hospital volume on processes of breast cancer care: A National Cancer Data

**Base study:** 573,571 women, 1755 different hospitals

[E. Pezzin PhD et. Al.](#),

- On multivariate analysis controlling for patient characteristics, treatment year and geographic location, hospital volume was a significant predictor for cancer diagnosis by initial biopsy negative surgical margins, and appropriate locoregional treatment

# Volume matters, sufficient evidence, G. Beets Brussels 2025

## Quality of surgeon/surgery matters



- Quality is difficult to measure – some surrogate markers
- Volume, with all its shortcomings, is consistently related to quality

JAMA Surgery | **Original Investigation**

### Low-Volume Elective Surgery and Outcomes in Medicare Beneficiaries Treated at Hospital Networks

Stanley Kalata, MD, MS; Sara L. Schaefer, MD; Ushapoorna Nuliyahu, MPH; Andrew M. Ibrahim, MD, MSc; Hari Nathan, MD, PhD

PRESIDENTIAL ADDRESS

### The Volume-Outcome Relationship in Cancer Surgery

*A Hard Sell*

*Ingemar Ihse, MD*



The NEW ENGLAND  
JOURNAL of MEDICINE

SPECIALTIES ▼ TOPICS ▼ MULTIMEDIA ▼ CURRENT ISSUE ▼ LEARNING/CME ▼ AUTHOR CENTER

EDITORIAL

### The Volume–Outcome Conundrum


Author: Kenneth W. Kizer, M.D., M.P.H. [Author Info & Affiliations](#)

OECD meeting 12-02-25, Brussels



# Volume matters, sufficient evidence

## Training matters



Review > [Cochrane Database Syst Rev.](#) 2012 Mar 14;(3):CD005391.  
doi: 10.1002/14651858.CD005391.pub3.

### Workload and surgeon's specialty for outcome after colorectal cancer surgery

David Archampong<sup>1</sup>, D: [Comparative Study](#) > [Br J Cancer.](#) 2004 May 17;90(10):1920-5. doi: 10.1038/sj.bjc.6601846.

### Why does specialist treatment of breast cancer improve survival? The role of surgical management

D Kingsmore<sup>1</sup>, D Hole, C Gillis  
> [Ann Surg Oncol.](#) 2003 Jul;10(6):606-15. doi: 10.1245/aso.2003.06.017.

### Breast cancer: do specialists make a difference?

Kristin A Skinner<sup>1</sup>, James T Helsper, Dennis Deapen, Wei Ye, Richard Sposto


17°C Bewolkt

Zoeken


NLD NL 13:05 4-6-2025

# Volume matters? Sufficient reason also to look into medical treatment, Jemma Boyle EJC 2023

a)




b)



# Complex discussion



- Low volume center natural variation and high volume center natural variation almost always lead to some low volume centers scoring better than some high volume centers.
- Mix of different arguments and interests: individual, group, institutional, patients, politicians etc.







# What drives centralisation in cancer care? Oesophagus

Melvin J Kilsdonk<sup>1,2</sup>, Sabine Siesling<sup>1,2</sup>, Boukje A C van Dijk<sup>1,3</sup>, Michel W Wouters<sup>4</sup>, Wim H van Harten<sup>2,4</sup>




## What drives centralisation in cancer care? Cystectomy

[Melvin J Kilsdonk<sup>1,2</sup>](#), [Sabine Siesling<sup>1,2</sup>](#), [Boukje A C van Dijk<sup>1,3</sup>](#), [Michel W Wouters<sup>4</sup>](#), [Wim H vanHarten](#)




# What drives centralisation?

- Scientific Evidence and Key Opinion Leaders: **some effect**
- External pressure (Public, Politicians, Patient groups, Payers) **more effective**
- **Examples of rigorous centralisation in Denmark, Ireland, Netherlands (Princess Maxima).**
- **Discussions ongoing in many countries**



# The Netherlands, volume norms proces

- 2010/11 Healthcare Inspectorate and Professional societies (SonCos) decide on minimum volumes of 20 for Pancreatic, Oesophagal and some rare cancers.
- Hematology A,B,C level centers in a national network
- 2011-2023 gradual implementation of minimum volume norms for many, interventions: Advanced Melanoma, Sarcoma, Gynecological tumors, Lung all 20, Adrenal 10, Breast Cancer and Colorectal 50, Head&Neck 200/80 new patients, Bladder 20 and Prostate 100 (both since 2019!) PLUS guidelines on Staffing, Infrastructure and Networking
- 2017/18 start Prinses Maxima (national) center for pediatric oncology after 5 years of discussion and conflict





# The Netherlands, Volume norms proces


- **National agreement forced upon the field by the Ministry, Patient organisations and Insurances; *targeted minimum 50-100 for Oncologic Surgery 2022:***
- Important changes, *first set after 3 years of discussion with* -Pancreas 150 new pts and 50 resections, 30 systemic therapy, RT 50
- -Lung cancer 60 (later 100) resections, 300 prevalent- & (all) 10 incident systemic therapies, RT 50
- -Oesophagus/Gastric 75 resections, 50 prevalent- & 10 incident systemic therapies, RT 50
- -Renal Cancer: 50 (partial) resections and focal treatments, 50 prevalent- & (all) 10 Incident systemic treatments
- **2025 decision on implementation per 7 Oncol. Networks, translation into financing (and €€-loss compensation) by end 2026.**






## Volume matters, sufficient evidence

- ❖ Mechanisms presumed, but not known in detail
- ❖ Statistical variation and vested interests confuse the discussion
- ❖ Strong alliances needed to enforce concentration decisions  
(Denmark, Ireland, Princess Maxima, Literature)
- ❖ Case Netherlands: very gradual, now further norms established for 5 tumor types
- ❖ Too early for A&D quantitative minimum volume norms



Core standard OECI, Surgical Oncology 47.154: “The cancer centre applies minimum numbers of surgical procedures per tumour type according to National / International guidelines”

Network standard: “Minimum volumes of patients per health care provider per cancer type are defined and monitored within the network.”



- **Center's responsibility:**

- -Apply minimum volume standards according to international trends and scientific evidence (even above- or in absence of national thresholds!)
- -Produce, monitor and publish data on care quality of both surgical and medical procedures, especially in critical volumes, and participate in benchmark sets.
- -Proactive participation in regional/national discussions on minimum volumes

**Set patient interests above vested institutional and -professional interests!**



# OECI Accreditation & Designation and Minimum Volumes

Thank You

**Prof. Wim H. van Harten**  
**Athens June 2025**

